Navigation Links
Aung FootHealth Clinics & Advanced Wound Care Center Enrolling Patients With Chronic Diabetic Foot Ulcers for Matrix Clinical Trial
Date:2/4/2008

TUCSON, Ariz., Feb. 4 /PRNewswire/ -- Aung FootHealth Clinics & Advanced Wound Care Center today announced it is recruiting patients with lower extremity diabetic foot ulcers to participate in the MATRIX clinical trial. The MATRIX trial will study the effects of Excellarate(TM) (GAM501) (Ad5PDGF-B/bovine Type I collagen gel) for the potential treatment of patients with neuropathic non-healing diabetic foot ulcers. Excellarate is an investigational product designed to stimulate the process of wound healing.

The MATRIX (A Phase 2b Study of GAM501 in the Treatment of Diabetic Ulcers in the Lower Extremities) trial is a randomized, double-blind, placebo-controlled, comparator arm (standard of care) safety and efficacy study to evaluate GAM501 (Ad5PDGF-B/bovine type I collagen gel) that is topically administered once or twice over the course of the study. The primary endpoint will be the effect of Excellarate on the incidence of complete ulcer closure at 12 weeks or earlier.

"The Excellarate topical gel using Gene Activated Matrix (GAM) technology is designed to provide localized and sustained cellular release of platelet-derived growth factor-BB protein (PDGF-BB). Sustained delivery of PDGF-BB directly at the wound site is believed to stimulate angiogenesis and granulation tissue formation through the recruitment and proliferation of chemotactic cells such as monocytes, fibroblasts, and endothelial cells, which are necessary for the stimulation of a variety of wound healing processes," stated Barbara J. Aung, DPM, CWS Aung FootHealth Clinics & Advanced Wound Care Center, and a trial investigator.

There are currently more than 20 million Americans who have diabetes and this number is expected to double by the year 2030. Many diabetic patients suffer from peripheral neuropathy, or a loss of feeling in their feet, that puts them at increased risk of foot ulceration. Over 850,000 chronic diabetic ulcers are diagnosed in the U.S. each year. Patients with non-healing ulcers are more susceptible to infections that may lead to amputation of the affected foot or leg.

Aung FootHealth Clinics & Advanced Wound Care Center is among an estimated 25 sites participating in the MATRIX trial. The trial is expected to enroll 210 patients nationwide. Prospective participants can call Aung FootHealth Clinics & Advanced Wound Care Center at (520) 886-9866 for more information about the study and eligibility.

For over 15 years Barbara J. Aung, DPM, CWS and Aung FootHealth Clinics & Advanced Wound Care Center has been a leader in the field of Podiatric Medicine specializing in Advanced Wound Care, Limb Preservation and Amputation Prevention. Most chronic/long standing wounds that are treated in our wound care center heal within 8-12 weeks. In fact, over 95% of the wounds that are treated heal fully. Using proven clinical pathways, our specifically trained staff provides comprehensive individualized treatment to patients.

Please visit our website at http://www.healthy-feet.com for additional information on "Keeping your Feet Healthy for the Journeys...Yet to be Made."


'/>"/>
SOURCE Aung FootHealth Clinics & Advanced Wound Care Center
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
2. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
3. Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint
4. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
5. Wyeths TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer
6. Siemens Showcases Its Most Comprehensive and Advanced Breast Care Portfolio
7. FDA Clears Advanced Test for Monitoring Metastatic Colorectal Cancer
8. New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer
9. Allos Therapeutics Initiates Study of RH1 in Patients with Advanced Solid Tumors or non-Hodgkins Lymphoma
10. Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium
11. New Data Examines the Effect of Adding a Statin to Optimized Treatment for Patients with Advanced Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 2016  Diplomat Pharmacy, Inc. (NYSE: DPLO) has been recognized by ... Workplaces National Standard. To learn more about Diplomat,s ... ... ... administered by WorkplaceDynamics, LLC, a research firm specializing in organizational health ...
(Date:12/8/2016)... Connecticut , 8 de dezembro de 2016  A Mederi Therapeutics ... terapia Stretta, um tratamento não cirúrgico para a doença do refluxo gastroesofágico (DRGE). ... ... Live Stretta procedure performed and ... of Endoscopy at Wuhan Union Hospital ...
(Date:12/8/2016)... Pa. , Dec. 8, 2016  A new ... reports that the use of opioid therapy to treat ... increase the likelihood of more harmful consequences, including death. ... , M.D., and Zankhana Mehta , M.D., authored ... research on chronic opioid therapy. The study was published ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... December 09, 2016 , ... Groth Family Insurance, a ... Richland, is initiating a charity drive to support the family of Cindy Hendrickson, ... collision. , On October 29th of this year, Cindy Hendrickson swerved to ...
(Date:12/9/2016)... ... December 09, 2016 , ... Sober College, the ... the grand opening of the Sober College Robert Pfeifer Memorial Learning Center at ... 2-3, and was attended by an overwhelming amount of alumni, family, colleagues and ...
(Date:12/9/2016)... ... ... "I had a terrible time trying to get my grandson to use his ... had a more child-friendly design, then children would be more likely to look forward ... avoid the need to deliver medication via a nebulizer mask. The design will not ...
(Date:12/8/2016)... ... December 08, 2016 , ... Russ ... announced the first national #QuackGivesBack campaign which supported local breast cancer organizations during ... franchise-wide Quack Gives Back initiative, and we’re very pleased with the ...
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for ... In Your Mouth?” (WIYM) campaign to inform dentists and patients about the safety issues ... implant and prosthetic market in the U.S. is projected to reach $6.4 billion in ...
Breaking Medicine News(10 mins):